U.S. markets closed

Celyad Oncology SA (CLYYF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
9.150.00 (0.00%)
At close: 5:33PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.15
Open9.15
BidN/A x N/A
AskN/A x N/A
Day's Range9.15 - 9.15
52 Week Range9.15 - 12.24
Volume1,500
Avg. Volume0
Market Cap60.555M
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day
      GlobeNewswire

      Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day

      Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM) showed dose dependent engraftment up to dose level three (300×106 cells per infusion) with no Graft-versus-Host disease reported to dateSubmission of IND application for CYAD-203, a new first-in-class shRNA-based allogeneic, IL-18-armored CAR T candidate, expected in mid-2022CYAD-101 following FOLFIRI preconditioning in advanced metastatic colorectal cancer (mCRC) was well-tolerated; cell kinetic and ac

    • Celyad Oncology to Host Virtual Research & Development Webinar on July 20th
      GlobeNewswire

      Celyad Oncology to Host Virtual Research & Development Webinar on July 20th

      MONT-SAINT-GUIBERT, Belgium, July 13, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it will host a Research & Development webinar on Tuesday, July 20th at 11:30 a.m. EDT. Members of the Celyad Oncology leadership team will provide an overview of the recent advances in the R&D pipeline including insights into new

    • Celyad Oncology to Participate at the William Blair Biotech Focus Conference 2021
      GlobeNewswire

      Celyad Oncology to Participate at the William Blair Biotech Focus Conference 2021

      MONT-SAINT-GUIBERT, Belgium, July 07, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Chief Scientific Officer, Dr. David Gilham, will participate in a panel discussion titled “Cell Therapies in the Next Decade” to be held on Wednesday, July 14th, at 08:55 a.m. EST at the William Blair Biotech Focus Conferenc